Despite these limitations, it is the first study, to our knowledge, to investigate the imaging features of a unique genetic variation in GBM that has been demonstrated to be a clinically significant positive prognostic factor independent of IDH mutation. This evidence concerns the gene IDH1 and glioblastoma.